Covid: Anvisa authorizes the use of Remdesivir for children and babies

The National Health Surveillance Agency (Anvisa) approved, this Monday (21/11), the use of the antiviral drug Remdesivir for children in the treatment of Covid-19.

The application of the medicine is allowed in babies and children from 28 days old weighing 3 kg or more, who have pneumonia and need oxygen supplementation. Children under 40 kg who don’t need oxygen, but are at risk of progressing to severe Covid-19 frames, can also take the medicine.

Remdesivir is an injectable antiviral approved by Anvisa since March 2021 for adults. The medicine prevents the coronavirus from replicating in the body, reducing the time of infection.

Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente🇧🇷

The post Covid: Anvisa authorizes the use of Remdesivir for children and babies first appeared on Metropolis.

Leave a Comment